PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors

By sjmartinez • September 1, 2024

Yap TA, Choudhury AD, Hamilton E, Rosen LS, Stratton KL, Gordon MS, Schaer D, Liu L, Zhang L, Mittapalli RK, Zhong W, Soman N, Tolcher AW. PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors. ESMO Open. 2024 Aug 29;9(9):103653. doi: 10.1016/j.esmoop.2024.103653. Epub ahead of print. PMID: 39214047.

Tags: advanced solid tumors, epithelial–mesenchymal transition, Hematology/Oncology, metastatic castration-resistant prostate cancer, Publications, TGF-β signaling, TGF-β-R1 inhibitor

Related Posts

Differences in treatment decision-making for non-small cell lung cancer among patients and physicians, by race and ethnicity

Dwyer Orr L, Vadagam P, Vanderpoel J, Patel MI, Basu Roy U, Ledezma B, Yung M, Deering KL, Kulbokas V, Feldman J, Gray JE. Differences[...]

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy

Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike[...]

Real world outcomes of patients with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation after induction with liposomal daunorubicin-cytarabine (CPX-351)

Ngo D, Kaleka G, Yang D, Mokhtari S, Tinajero J, Marcucci G, Nakamura R, Pullarkat V, Oliai C, Salhotra A. Real world outcomes of patients[...]